ReviewEndocrine pathology2008
Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.
Review in Endocrine pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors.Neuroendocrinology · 2017Pooled it
- Article
- Goblet cell carcinoid of the appendix: Six case reports.World journal of clinical cases · 2024Article
- High Ki67 Gene Expression Is Associated With Aggressive Phenotype in Hepatocellular Carcinoma.World journal of oncology · 2024Article
- A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.NPJ systems biology and applications · 2023Article
- Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).Cancers · 2022Review
- Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms.BioMed research international · 2022Article
- Article
- Small Bowel Neuroendocrine Tumors.Current problems in surgery · 2020Article
- STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Article
- Prognostic value of a three-scale grading system based on combining molecular imaging withOncotarget · 2020Article
- Predicting Metastasis Risk in Pancreatic Neuroendocrine Tumors Using Deep Learning Image Analysis.Frontiers in oncology · 2020Article
- Goblet cell carcinoid of the appendix: Two case reports and a review of the literature.Molecular and clinical oncology · 2019Article
- A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019Article
- A well differentiated neuroendocrine tumor of the jejunum with peritoneal carcinomatosis: A case report.Molecular and clinical oncology · 2018Article
- A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis.Oncotarget · 2018Article
- Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2017Article
- Principles of diagnosis and management of neuroendocrine tumours.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Review
- siRNA targeting YAP gene inhibits gastric carcinoma growth and tumor metastasis in SCID mice.Oncology letters · 2016Article
- Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors.Virchows Archiv : an international journal of pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP-NETS) are unusual and rare neoplasms for which prognostic assessment and the diagnosis of malignancy, on the basis of histology alone, represent considerable challenges for the pathologist. To date, many molecular markers have been identified with a view to providing accurate and timely prediction of response to treatment and long-term survival. Proliferation remains a key feature of tumor progression, which has been widely estimated by the immunohistochemical use of the Ki-67 nuclear antigen. Given the continued difficulties inherent in prediction of malignancy in pancreatic neuroendocrine tumors (PETs) in particular, it has become unclear whether Ki-67 is truly a reliable prognostication marker. This review seeks to better establish what the consensus is on the role of the Ki-67 proliferation index as a prognostic indicator of long-term outcome in pancreatic neuroendocrine tumors. We conclude that most studies favor the utility of the Ki-67 proliferation index despite different critical percentages and in concert with other pathological parameters in the routine work-up of PETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.